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Some studies suggest thyroid hormones may regulate the human immune system. In order to evaluate the effect of thyroid hormone
deficiency on antibody production, we evaluated serum IgA and IgM concentrations in 83 children with congenital hypothyroidism (CH),
diagnosed by neonatal screening. Patients were compared to two healthy, age-matched control groups. Patients with permanent CH had a
significantly higher frequency of undetectable IgA concentrations (thyroid agenesis, P < 105; thyroid ectopy, P = 0.013) and lower
concentrations of IgA (thyroid agenesis, P < 106; thyroid ectopy, P < 105; dyshormonogenesis, P = 0.0002) and IgM (thyroid agenesis, P =
0.0002; thyroid ectopy, P < 106; dyshormonogenesis, P = 0.0017) compared to control group. No difference was observed between patients
with transient hypothyroidism and controls. A significant correlation was observed between serum IgA and IgM concentrations and fT4
levels. IgA and IgM deficiency is correlated with the severity of congenital hypothyroidism and may help to evaluate the duration and
severity of thyroid hormone deficiency during prenatal life.
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Thyroid hormones are known to influence many human
cells and control the development and function of many
organs.
Interactions between thyroid hormones and the immune
system development and function have been demonstrated
in experimental studies on animals. The first studies, carried
out more than 70 years ago, showed that adenohypophysis
ablation caused thymic atrophy in mice [1]. Similarly, a
report on humans showed that thymic development was
significantly reduced and thymic tissue was atrophic in
patients with sporadic congenital hypothyroidism [2]. In
more recent years, several studies have clarified the role of1521-6616/$ - see front matter D 2005 Published by Elsevier Inc.
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[3–8].
B cell development is defective in genetically hypo-
thyroid mice, such as dw/dw [3,9], hyt/hyt [3], and TRa/
inbred mice [5]. Similarly, B cell lymphopoiesis, but not T
cell production, is affected by thyroid hormone deficiency in
hyt/hyt mice [3]. Secondary lymphocyte development,
however, is normal in both dw/dw and hyt/hyt mice, and a
normal humoral response to T-dependent and T-independent
antigens has been demonstrated in those animals [3,10].
Although case reports have been published on the
immune function in hypothyroid patients [11–14], the
interaction between thyroid hormones and the immune
system development and function in humans has not been
completely clarified. The aim of the present study was to
evaluate the role of hypothyroidism on immunoglobulin
levels in children with congenital hypothyroidism at the
time of diagnosis.16 (2005) 94 – 98
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16 10M, 6F 33.2 T 10.5 13 breast,
3 bottle
Dyshormonogenesis 17 10M, 7F 33.7 T 18.6 14 breast,
3 bottle
Thyroid ectopy 30 11M, 19F 22.6 T 6.4 27 breast,
3 bottle
Thyroid agenesis 20 4M, 16F 25.0 T 7.2 15 breast,
5 bottle
Total 83 35M, 48F 27.5 T 11.8 69 breast,
14 bottle
Control group 1 102 56M, 46F 36.8 T 15.5 80 breast,
22 bottle
Control group 2 49 21M, 28F 22.7 T 7.1 37 breast,
12 bottle
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Patients
Eighty-three patients (35 males, 48 females, born full-
term), diagnosed with congenital hypothyroidism, were
included in the study. The patients were divided into four
groups, according to their diagnosis. Sixteen patients had
transient hypothyroidism, 17 had dyshormonogenesis, 30
had thyroid ectopy, and 20 had thyroid agenesis. Thyroid
agenesis was diagnosed when a 99mTc-pertechnetate
thyroid scan, performed at the time of diagnosis, showed
no radionuclide uptake. Thyroid ectopy was diagnosed
when a 99mTc-pertechnetate thyroid scan showed either a
smaller volume of thyroid or its abnormal position.
Dyshormonogenesis was diagnosed when a normal or
increased uptake of 99mTc was revealed in a position that
is normal for the thyroid gland [15]. Transient neonatal
hypothyroidism was diagnosed in the presence of
increased concentrations of thyroid stimulating hormone
(TSH) with normal or decreased fT4, both returning to
normal levels within 1 month after birth and associated
with normal thyroid morphology and normal 99mTc
uptake [16].
The biochemical severity of congenital hypothyroidism
was assessed from the first quantitative thyroxine (fT4) and
thyroid-stimulating hormone (TSH) measurements, before
initiation of thyroid replacement therapy. Since thyroid
ectopy and thyroid agenesis are usually diagnosed at an
earlier age than transient hypothyroidism and dyshormono-
genesis because of the severity of the symptoms, two
different control groups, matched for sex and age, were
enrolled in the study. Control group 1 included 102 healthy
controls, sex- and age-matched with the transient hypo-
thyroidism and dyshormonogenesis group. Control group 2
included 49 healthy controls, sex- and age-matched with the
thyroid ectopy and thyroid agenesis group. All the control
children underwent a review of their medical history, a
physical examination and a nutritional assessment, as well
as biochemical and endocrine examinations. The main
features of the patient and control groups (sex and age at
diagnosis, and type of feeding) and the diagnosis are
reported in Table 1.
The ethics committee of Meyer Children’s Hospital
approved the study; informed written consent was obtained
from the parents of all subjects.
Laboratory methods
Free-T4 and TSH serum levels were determined by
immunometric assays (Immulitei 2000 Third generation,
DPC Diagnostic Products Corporation, Los Angeles, CA,
USA). Within- and between-run coefficients of variation
were less than 12.5% for TSH, and were less than 7.5% for
fT4. The normal range of fT4 and TSH serum concentrations
were 0.8–1.9 ng/dl and 0.4–4 AUI/ml.Immunoglobulin concentrations were measured by
ELISA (IgA-human-ELISA quantitation kit and IgM-
human-ELISA quantitation kit, Vinci Biochem, Vinci,
Italy). Values lower than 10 mg/dl for IgA and lower
than 20 mg/dl for IgM were retested by radial immuno-
diffusion technique (The Binding Site, Birmingham UK;
lower limit of detection: 0.8 mg/dl for IgA and 0.7 mg/dl
for IgM), using serum dilution when appropriate. IgA
concentrations were considered undetectable when they
were <0.8 mg/dl in two separate assays. The intra- and
inter-assay coefficients of variation for IgA and IgM
concentrations were less than 2.1 and 2.7%, respectively.
CD19+ B cells, as well as B cells bearing surface
membrane IgM/IgD [SmIg(D+M+)], were enumerated by
flow cytometry using fluorescein or phycoerythrin-con-
jugated monoclonal antibodies (Becton Dickinson, San
Jose´, CA, USA). Flow cytometry was performed on a
Becton-Dickinson FACScan (Becton-Dickinson, San Jose,
CA, USA) immediately after cell staining.
Differences between means (analyzed by the Student’s t
test for unpaired samples), differences in frequencies
(evaluated by v2 test or Fisher’s exact probabilities, as
appropriate), and correlation analyses (Pearson) were
measured using an SPSSX statistical package (SPSS Inc.,
Chicago, IL). For analysis of correlation, TSH values over
100 lUI/ml were considered as 100. For the same purposes,
fT4 values less than 0.1 ng/dl were considered as 0.1 and
IgA values less than 0.8 mg/dl were considered as 0.8. Two-
tailed P values were determined and P values < 0.05 were
considered significant.Results
No abnormalities were found in the medical history, the
physical examination, the nutritional assessment, and the bio-
chemical or endocrine examination within the control groups.
S. Stagi et al. / Clinical Immunology 116 (2005) 94–9896No differences were found in the sex distribution and
mean age between any group of patients and their control
group. Similarly, no differences in type of feeding were
found between any of the four groups of patients and their
control group. Within the control groups, no difference was
found in serum IgA and IgM concentration between males
and females.
The frequency of undetectable serum IgA was signifi-
cantly higher in patients with thyroid agenesis (12/20,
60%) and thyroid ectopy (7/30, 23.3%), compared to their
control group (2/49, 4.1%), while no difference was found
between serum IgA concentrations of patients with
dyshormonogenesis (2/17, 11.8%) or transient hypothy-
roidism (0/16) and their controls (3/102, 2.9%). Data are
shown in Table 2. Compared to control group 1, the
frequency of undetectable serum IgA was higher, and the
serum IgA concentrations were lower, as expected, in
control group 2 (younger controls), but this difference did
not reach statistical significance. Serum IgA concentrations
were significantly lower in patients with thyroid agenesis
or thyroid ectopy or dyshormonogenesis compared to their
control groups. No difference was found between serum
IgA concentrations in patients with transient hypothyroid-
ism and their control. Data are shown in Table 2. IgM
concentrations were significantly lower in patients with
thyroid agenesis, thyroid ectopy, and dyshormonogenesis,
compared to their control groups, while no difference was
found between IgM concentrations of patients with
transient hypothyroidism and their control group (Table
2). In evaluating all groups of patients, a correlation was
found between fT4 levels and serum IgA concentrations
(r = 0.74; P < 105) and between fT4 and serum IgM
concentrations (r = 0.52; P < 105). A negative correlation
was found between IgA concentrations and TSH (r =
0.56, P < 105) and between IgM concentrations and
TSH (r = 0.46 P < 105). The percentage of CD19+ and
SmIg(D+M+) B cells was 17.9 (range 9–29) and 16.3
(range 8–24), respectively, in the 83 patients included in
the study [normal value 6–25 % for both CD19+ and
SmIg(D+M+) cells].Table 2
IgA and IgM serum concentrations in hypothyroidism patients and control group







40.4 T 15.7 ns 0
Dyshormonogenesis 28.6 T 9.9 0.0017 2
Control group 1 41.6 T 15.4 – 3/1
Thyroid ectopy 23.2 T 5.9 <106 7
Thyroid agenesis 22.1 T 6.9 0.0002 12
Control group 2 38.8 T 15.2 – 2
ns = Not significant.
SD = standard deviation.
a Undetectable IgA was defined as IgA < 0.8 mg/dl.Discussion
Increasing evidence shows that the immune system
operates in a coordinated way with the neuroendocrine
system and that immune cells can be influenced by
hormones, neurotransmitters, and neuropeptides [17,18].
The present study shows that children with permanent
congenital hypothyroidism (thyroid agenesis, thyroid
ectopy, dyshormonogenesis) have a defect in immunoglo-
bulin production. The frequency of undetectable serum IgA
concentrations is significantly higher in patients with these
disorders than in controls and the defect is more common in
patients with the most severe hypothyroidism. Similarly,
serum IgM concentrations are significantly lower in patients
with hypothyroidism and there is a strong correlation
between the concentrations of IgA or IgM and the
concentrations of fT4. The IgG level was not considered
as a reliable parameter for evaluation of antibody production
in the neonate because neonatal serum IgG concentrations
reflect the transplacental passage of IgG from the mother in
the third trimester, rather than the neonatal antibody
synthesis. In contrast to infants with persistent hypothyroid-
ism, the frequency of undetectable serum IgA concentra-
tions in patients with neonatal transitory hypothyroidism is
identical to that found in healthy controls. Furthermore, IgM
concentrations are also normal in transitory hypothyroidism
patients. These data suggest that transitory hypothyroidism
has no effect on B cell development and/or function. These
findings differ from data obtained in animal studies that
demonstrate that transitory propylthiouracil-induced hypo-
thyroidism in the earliest phases of development causes
transient changes in thymic T cell development in immune
cell sub-populations and delayed B cell development.
However, immunoglobulin concentrations were not reported
in those studies [19].
It is not easy to speculate whether the effect of fT4
deficiency acts directly on B cell function or if it is
dependent on other factors. In humans, thyroid hormones
exert immunomodulatory activities and the thymus is one of




P IgA levels (mg/dl),
mean T SD
P
/16 (0) 0.64 7.2 T 7.4 ns
/17 (11.8) 0.14 4.5 T 2.6 0.0002
02 (2.9) – 11.1 T 7.0 –
/30 (23.3) 0.013 2.6 T 2.4 <105
/20 (60.0) <105 0.9 T 0.2 <106
/49 (4.1) – 9.2 T 6.9 –
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strated that thyroid hormones have a direct role in B cell
development and that they are required for normal B cell
production in the bone marrow [3,4]. In the present study,
no decrease in the percentage of CD19+ or SmIg(D+M+) B
cells was demonstrated in any of the groups of patients
studied. The defect of immunoglobulin production, there-
fore, does not seem to be due to a reduction of antibody-
producing cells but to a functional defect.
On the other hand, it cannot be excluded that immuno-
globulin production defect in hypothyroidism patients is
related to the high levels of TSH present in these patients.
Thyroid-stimulating hormone has a variety of immune-
regulating cytokine-like activities that can influence T cell
development in the thymus and intestine, and affect humoral
and cell-mediated responses of peripheral lymphocytes [21].
Many hematopoietic cells in the bone marrow produce TSH
and express the TSH receptor, as do subsets of dendritic
cells, monocytes, and lymphocytes in the spleen and lymph
nodes [21].
Another mechanism could be hypothesized: the action of
the TSH and thyroid hormone could be mediated by other
hormones or neurotransmitters. For example, thyroid
hormones have a permissive action on the adrenergic
function and patients with untreated hypothyroidism have
a down-regulation of the adrenergic receptor [22–24].
Adrenergic stimulation increases antibody production by B
cells [18]. Therefore, the effect of hypothyroidism on IgA
and IgM synthesis might be mediated by adrenergic down-
regulation. Experiments performed on animals demonstrate
that both beta-adrenergic receptor expression and IgM
production are increased in hyperthyroid mice and
decreased in hypothyroid mice after immunization and that
IgM production is related to regulation of beta-adrenergic
receptors on immune cells [25]. The low levels of IgA and
IgM found in patients with congenital hypothyroidism did
not result in an increased number or severity of infections. It
may be hypothesized that the normal values of serum IgG
concentrations, due to the transplacental passage of that
isotype of immunoglobulin, are a sufficient help against
infections in these patients during the first months of life.
The follow-up of patients included in the present study,
ongoing in our clinic, will clarify whether low serum IgM or
IgA concentrations are associated with a suboptimal
response to immunization.
Patients with untreated congenital hypothyroidism usu-
ally have severe neurological and growth impairment [26],
and even patients who are treated promptly may have
neurological damage and mild motor and neuropsycholo-
gical impairment [26].
Many parameters (fT4 level at birth, TSH level at birth,
age at diagnosis, age of treatment start, initial thyroid
replacement therapy dosage, bone age at birth, electro-
encephalogram at birth) have been reported to be prognostic
factors for growth or neuropsychological development [27–
31]. Some of these features have also been used asindicators of the severity of prenatal thyroid hormone
deficiency. However, none of these parameters accurately
reflect the severity or age at onset of hormone deficiency
during fetal life.
The present study shows that patients with permanent
congenital hypothyroidism have lower concentrations of
IgM than controls and an extremely high frequency of
undetectable serum IgA concentrations. IgM serum concen-
trations are directly related to the severity of hormone
deficiency and the lowest values of IgM can be found in
those patients (thyroid agenesis, thyroid ectopy) in which
the defects have their onset earlier during prenatal life.
Therefore, the presence of normal levels of IgM or IgA in an
infant with hypothyroidism could be considered as a
positive prognostic factor, suggesting a less severe defi-
ciency of thyroid hormones or a later age of onset during
fetal life. Long-term follow-up of patients included in the
present study will clarify whether serum IgM or IgA
concentrations also predict the prognosis for neurological
development or growth of congenital hypothyroidism
patients. Preliminary data suggest that serum IgA and IgM
concentrations gradually increase after l-thyroxine therapy
has started. Further studies are also necessary to clarify the
mechanisms underlying the thyroid control of antibody
production in congenital hypothyroidism.Acknowledgment
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